Literature DB >> 22974563

A mechanistic compartmental model for total antibody uptake in tumors.

Greg M Thurber1, K Dane Wittrup.   

Abstract

Antibodies are under development to treat a variety of cancers, such as lymphomas, colon, and breast cancer. A major limitation to greater efficacy for this class of drugs is poor distribution in vivo. Localization of antibodies occurs slowly, often in insufficient therapeutic amounts, and distributes heterogeneously throughout the tumor. While the microdistribution around individual vessels is important for many therapies, the total amount of antibody localized in the tumor is paramount for many applications such as imaging, determining the therapeutic index with antibody drug conjugates, and dosing in radioimmunotherapy. With imaging and pretargeted therapeutic strategies, the time course of uptake is critical in determining when to take an image or deliver a secondary reagent. We present here a simple mechanistic model of antibody uptake and retention that captures the major rates that determine the time course of antibody concentration within a tumor including dose, affinity, plasma clearance, target expression, internalization, permeability, and vascularization. Since many of the parameters are known or can be estimated in vitro, this model can approximate the time course of antibody concentration in tumors to aid in experimental design, data interpretation, and strategies to improve localization.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22974563      PMCID: PMC3729444          DOI: 10.1016/j.jtbi.2012.08.034

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  76 in total

1.  The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue.

Authors:  A Krogh
Journal:  J Physiol       Date:  1919-05-20       Impact factor: 5.182

2.  Scaling rules for diffusive drug delivery in tumor and normal tissues.

Authors:  James W Baish; Triantafyllos Stylianopoulos; Ryan M Lanning; Walid S Kamoun; Dai Fukumura; Lance L Munn; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-11       Impact factor: 11.205

3.  Microvascular studies on the origins of perfusion-limited hypoxia.

Authors:  M W Dewhirst; H Kimura; S W Rehmus; R D Braun; D Papahadjopoulos; K Hong; T W Secomb
Journal:  Br J Cancer Suppl       Date:  1996-07

4.  Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery.

Authors:  A Krol; J Maresca; M W Dewhirst; F Yuan
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

5.  Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies.

Authors:  M H Kranenborg; O C Boerman; J C Oosterwijk-Wakka; M C de Weijert; F H Corstens; E Oosterwijk
Journal:  Int J Cancer       Date:  1998-01-05       Impact factor: 7.396

6.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy.

Authors:  Y Boucher; L T Baxter; R K Jain
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

7.  Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.

Authors:  Robert M Sharkey; Habibe Karacay; Heidi Richel; William J McBride; Edmund A Rossi; Ken Chang; Dion Yeldell; Gary L Griffiths; Hans J Hansen; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

8.  A33 antigen displays persistent surface expression.

Authors:  Margaret E Ackerman; Cecile Chalouni; Michael M Schmidt; Vivek V Raman; Gerd Ritter; Lloyd J Old; Ira Mellman; K Dane Wittrup
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

9.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse.

Authors:  Y Boucher; R K Jain
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

10.  Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.

Authors:  O W Press; D Shan; J Howell-Clark; J Eary; F R Appelbaum; D Matthews; D J King; A M Haines; P Hamann; L Hinman; D Shochat; I D Bernstein
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

View more
  43 in total

1.  Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.

Authors:  Eben L Rosenthal; Jason M Warram; Esther de Boer; Thomas K Chung; Melissa L Korb; Margie Brandwein-Gensler; Theresa V Strong; Cecelia E Schmalbach; Anthony B Morlandt; Garima Agarwal; Yolanda E Hartman; William R Carroll; Joshua S Richman; Lisa K Clemons; Lisle M Nabell; Kurt R Zinn
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

2.  Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.

Authors:  Katie F Maass; Chethana Kulkarni; Alison M Betts; K Dane Wittrup
Journal:  AAPS J       Date:  2016-02-24       Impact factor: 4.009

3.  Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Authors:  Sameed Ahmed; Miandra Ellis; Hongshan Li; Luca Pallucchini; Andrew M Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-29       Impact factor: 2.745

4.  QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models.

Authors:  Yougan Cheng; Craig J Thalhauser; Shepard Smithline; Jyotsna Pagidala; Marko Miladinov; Heather E Vezina; Manish Gupta; Tarek A Leil; Brian J Schmidt
Journal:  AAPS J       Date:  2017-05-24       Impact factor: 4.009

5.  A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate.

Authors:  Dhaval K Shah; Lindsay E King; Xiaogang Han; Jo-Ann Wentland; Yanhua Zhang; Judy Lucas; Nahor Haddish-Berhane; Alison Betts; Mauricio Leal
Journal:  AAPS J       Date:  2014-03-01       Impact factor: 4.009

6.  Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging.

Authors:  Kelly D Orcutt; Gregory P Adams; Anna M Wu; Matthew D Silva; Catey Harwell; Jack Hoppin; Manabu Matsumura; Masakatsu Kotsuma; Jonathan Greenberg; Andrew M Scott; Robert A Beckman
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

7.  Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Authors:  Christina Claus; Claudia Ferrara; Wei Xu; Johannes Sam; Sabine Lang; Franziska Uhlenbrock; Rosmarie Albrecht; Sylvia Herter; Ramona Schlenker; Tamara Hüsser; Sarah Diggelmann; John Challier; Ekkehard Mössner; Ralf J Hosse; Thomas Hofer; Peter Brünker; Catherine Joseph; Jörg Benz; Philippe Ringler; Henning Stahlberg; Matthias Lauer; Mario Perro; Stanford Chen; Christine Küttel; Preethi L Bhavani Mohan; Valeria Nicolini; Martina Carola Birk; Amandine Ongaro; Christophe Prince; Reto Gianotti; Gregory Dugan; Christopher T Whitlow; Kiran Kumar Solingapuram Sai; David L Caudell; Armando G Burgos-Rodriguez; J Mark Cline; Michael Hettich; Maurizio Ceppi; Anna Maria Giusti; Flavio Crameri; Wouter Driessen; Peter N Morcos; Anne Freimoser-Grundschober; Victor Levitsky; Maria Amann; Sandra Grau-Richards; Thomas von Hirschheydt; Stella Tournaviti; Michael Mølhøj; Tanja Fauti; Viola Heinzelmann-Schwarz; Volker Teichgräber; Sara Colombetti; Marina Bacac; Alfred Zippelius; Christian Klein; Pablo Umaña
Journal:  Sci Transl Med       Date:  2019-06-12       Impact factor: 17.956

8.  Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer.

Authors:  Kimberly Kanigel Winner; Mara P Steinkamp; Rebecca J Lee; Maciej Swat; Carolyn Y Muller; Melanie E Moses; Yi Jiang; Bridget S Wilson
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

9.  Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging.

Authors:  Kenneth M Tichauer; Sophie J Deharvengt; Kimberley S Samkoe; Jason R Gunn; Marcus W Bosenberg; Mary-Jo Turk; Tayyaba Hasan; Radu V Stan; Brian W Pogue
Journal:  Mol Imaging Biol       Date:  2013-11-12       Impact factor: 3.488

10.  Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

Authors:  Alison M Betts; Nahor Haddish-Berhane; John Tolsma; Paul Jasper; Lindsay E King; Yongliang Sun; Subramanyam Chakrapani; Boris Shor; Joseph Boni; Theodore R Johnson
Journal:  AAPS J       Date:  2016-05-19       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.